Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adults Aged 18 Years and Older

Status: Completed
Location: See all (25) locations...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY

The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular (IM) injection of up to 3 dose levels of Quadrivalent Influenza mRNA Vaccine MRT5410 compared to an active control (QIV SD, QIV HD \[adults ≥ 65 years of age only\], or RIV4) in adults 18 years of age and older.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:

• Aged 18 years on the day of inclusion (US) and aged 21 years on the day of inclusion (Puerto Rico)

• A female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies:

⁃ Is of non-childbearing potential. To be considered of non-childbearing potential, a female must be postmenopausal for at least 1 year, or surgically sterile OR Is of childbearing potential and agrees to use an effective contraceptive method or abstinence from at least 4 weeks prior to study intervention administration until at least 12 weeks after study intervention administration.

Locations
United States
California
Joint Clinical Trials Huntington Park Site Number : 8400032
Huntington Park
Long Beach Clinical Trials Site Number : 8400056
Long Beach
Velocity Clinical Research, North Hollywood Site Number : 8400063
North Hollywood
California Research Foundation Site Number : 8400001
San Diego
Florida
SIMEDHealth, LLC Site Number : 8400042
Gainesville
Indago Research and Health Center Site Number : 8400002
Hialeah
Research Centers of America Site Number : 8400011
Hollywood
Florida International Research Center Site Number : 8400009
Miami
Palm Beach Research Center Site Number : 8400041
West Palm Beach
Idaho
Velocity Clinical Research Site Number : 8400024
Meridian
Indiana
Brengle Family Medicine Site Number : 8400040
Indianapolis
Kentucky
AMR Lexington Site Number : 8400035
Lexington
Nebraska
Meridian Clinical Research Site Number : 8400017
Norfolk
Velocity Clinical Research Site Number : 8400034
Omaha
Nevada
WR-CRCN, LLC Site Number : 8400060
Las Vegas
South Carolina
Coastal Carolina Research Center - N Charleston Site Number : 8400007
North Charleston
Tennessee
AMR Knoxville Site Number : 8400021
Knoxville
Texas
Elligo Health Research, Inc. Site Number : 8400037
Austin
Tekton Research, Inc Site Number : 8400051
Austin
DM Clinical Research Site Number : 8400046
Humble
Clinical Trials of Texas, Inc. - PPDS Site Number : 8400043
San Antonio
DM Clinical Research - Sugar Land Site Number : 8400045
Sugar Land
Martin Diagnostic Clinic Site Number : 8400058
Tomball
Other Locations
Puerto Rico
Investigational Site Number : 6300002
Barrio Sabana
Investigational Site Number : 6300001
San Juan
Time Frame
Start Date: 2022-11-28
Completion Date: 2024-03-28
Participants
Target number of participants: 682
Treatments
Experimental: Group 1: Quadrivalent Influenza mRNA Vaccine MRT5410 low dose
participants will receive a single dose (low) of QIV mRNA vaccine
Experimental: Group 2: Quadrivalent Influenza mRNA Vaccine MRT5410 medium dose
participants will receive a single dose (medium) of QIV mRNA vaccine
Experimental: Group 3: Quadrivalent Influenza mRNA Vaccine MRT5410 high dose
participants will receive a single dose (high) of QIV mRNA vaccine
Active_comparator: Group 4: RIV4
participants will receive a single dose of RIV4 vaccine
Active_comparator: Group 5: QIV-SD
participants will receive a single dose of QIV-SD vaccine
Active_comparator: Group 6: QIV-HD
participants will receive a single dose of QIV -HD vaccine
Related Therapeutic Areas
Sponsors
Leads: Sanofi Pasteur, a Sanofi Company

This content was sourced from clinicaltrials.gov